# Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

> **NCT00650156** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 24 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT00650156
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650156, "Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00650156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*